Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGR Regimen in High-risk Treatment-naive Follicular Lymphoma
NCT06549335Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in follicular lymphoma (FL), sponsored by Ruijin Hospital. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06549335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549335.